CLOV

TentativeAI MemoPost-earnings T+3

Clover Health Investments

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and raised FY2026 guidance • 2026-08-05

Base target: $5 / p=50% prob

Biggest risk

The stock now faces a higher expectation bar. Medical-cost trends, cohort economics, and the durability of profitability must remain favorable; recent insider sales and a reported cyber incident add sentiment and execution risks.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The Q2 print materially strengthened the operating thesis: rapid Medicare Advantage membership growth, positive GAAP earnings, higher revenue and gross-profit guidance, and improving profitability support a continued rerating if execution holds [#SEC-8K-2026-08-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print follow-through against the raised guide
Cohort maturation and 4.5-Star payment-year economics
The Q2 print materially strengthened the operating thesis: rapid Medicare Advantage membership growth, positive GAAP earnings, higher revenue and gross-profit guidance, and improving profitability support a continued rerating if execution holds [#SEC-8K-2026-08-05].

BearKey bullets

2027 earnings potential depends on cohort maturation and realization of the 4.5-Star payment-year benefit.
No post-Q2 analyst target, rating, or estimate-revision set was identified, limiting confidence in the expectation-gap analysis.
Raised FY2026 guidance becomes the key execution bar; deterioration in medical costs, membership, gross profit, EBITDA, or GAAP income could reverse the post-print move [#SEC-8K-2026-08-05].

WatchKey bullets

Q2 2026 results and raised FY2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $5 (p=50%)

Target spread vs base: +25% / -30%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $5 (p=50%)Bear Target: $4 (p=25%)

Commentary

The company-source evidence is positive after the Q2 report and guidance raise [#SEC-8K-2026-08-05]. MarketBeat's earnings page showed CLOV at $4.76, up 2.15% on August 8, and linked coverage reporting a roughly 20% post-print surge tied to the Q2 beat and guidance raise [MarketBeat](https://www.marketbeat.com/earnings/reports/2026-8-5-clover-health-investments-corp-stock/). Canaccord's latest identified target action was positive but pre-print; no later analyst revisions were found. Direct MA comparators improve the peer context, but this remains a positive monitoring view rather than a high-conviction call.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print follow-through against the raised guide
Cohort maturation and 4.5-Star payment-year economics

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$5 / p=50% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-05
Q2 2026 results and raised FY2026 guidance
Clover reported $743 million of Q2 revenue, $28 million of GAAP net income, 157,309 Medicare Advantage members, and $41 million of adjusted EBITDA, while raising full-year revenue, gross profit, EBITDA, membership, and GAAP-income guidance [#SEC-8K-2026-08-05].
Prob 88.00% • Move 10.00% • Priced-in 72.00%

Short-term Catalysts

Next few weeks

Post-print follow-through against the raised guide
2026-11-06
Near-term momentum depends on whether investors continue to credit the raised outlook and whether subsequent results validate medical-cost, membership, gross-profit, EBITDA, and GAAP-profit trends [#SEC-8K-2026-08-05].
Prob 62% • Move 8% • Priced-in 65%

Long-term Catalysts

Months to a year

Cohort maturation and 4.5-Star payment-year economics
2027-01-01
Management cited stronger cohort development, continued clinical engagement, and the added flexibility of a 4.5-Star payment year as support for its 2027 outlook [#SEC-8K-2026-08-05].
Prob 70% • Move 18% • Priced-in 58%

Risks

2027 earnings potential depends on cohort maturation and realization of the 4.5-Star payment-year benefit.
No post-Q2 analyst target, rating, or estimate-revision set was identified, limiting confidence in the expectation-gap analysis.
Raised FY2026 guidance becomes the key execution bar; deterioration in medical costs, membership, gross profit, EBITDA, or GAAP income could reverse the post-print move [#SEC-8K-2026-08-05].
Recent insider activity included a July 20 open-market sale by Chief Legal Officer Karen Soares [#SEC-FORM4-2026-07-20].
Reuters reported that employee accounts were accessed in a cyber incident; operational, legal, and reputational follow-through is unclear.

Peers

Symbol	Summary
ALHC	Alignment Healthcare is a direct publicly traded Medicare Advantage comparator. Clover's 2025 10-K lists Alignment Health among regional MA competitors [#10-K-2026-02-27].
OSCR	Oscar Health is a publicly traded healthcare-technology and insurance comparator that Clover's 2025 10-K identifies among regional MA competitors [#10-K-2026-02-27].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ALHC

Alignment Healthcare is a direct publicly traded Medicare Advantage comparator. Clover's 2025 10-K lists Alignment Health among regional MA competitors [#10-K-2026-02-27].

OSCR

Oscar Health is a publicly traded healthcare-technology and insurance comparator that Clover's 2025 10-K identifies among regional MA competitors [#10-K-2026-02-27].